应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01558 东阳光长江药业
交易中 07-03 10:19:09
9.140
+0.150
+1.67%
最高
9.140
最低
8.990
成交量
2.94万
今开
8.990
昨收
8.990
日振幅
1.67%
总市值
80.43亿
流通市值
59.75亿
总股本
8.80亿
成交额
26.64万
换手率
0.00%
流通股本
6.54亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
东阳光长江药业早盘涨超3% 公司有望获纳入港股通名单
新浪港股 · 06-28
东阳光长江药业早盘涨超3% 公司有望获纳入港股通名单
港股异动 | 东阳光长江药业(01558)早盘涨超3% 恒生综合指数即将进行定期检讨 公司有望获纳入港股通名单
智通财经 · 06-28
港股异动 | 东阳光长江药业(01558)早盘涨超3% 恒生综合指数即将进行定期检讨 公司有望获纳入港股通名单
路演实录|东阳光长江药业(01558):聚焦三大领域 一体化释放长期价值
智通财经 · 06-27
路演实录|东阳光长江药业(01558):聚焦三大领域 一体化释放长期价值
东阳光长江药业(01558)上涨5.09%,报9.5元/股
金融界 · 06-25
东阳光长江药业(01558)上涨5.09%,报9.5元/股
东阳光长江药业盘中异动 股价大涨5.10%
自选股智能写手 · 06-25
东阳光长江药业盘中异动 股价大涨5.10%
一体化合并加速释放研产销竞争优势,“入通”或为东阳光长江药业(01558)估值跃迁起点
智通财经网 · 06-20
一体化合并加速释放研产销竞争优势,“入通”或为东阳光长江药业(01558)估值跃迁起点
东阳光长江药业06月18日主力资金流入21万元 连续3日加仓
自选股智能写手 · 06-18
东阳光长江药业06月18日主力资金流入21万元 连续3日加仓
东阳光长江药业06月11日获主力加仓234万元 环比增加333.33%
自选股智能写手 · 06-11
东阳光长江药业06月11日获主力加仓234万元 环比增加333.33%
东阳光长江药业:发布2023年年报补充公告
金融界港股 · 06-07
东阳光长江药业:发布2023年年报补充公告
东阳光长江药业(01558):选举唐新发为董事长
智通财经 · 06-07
东阳光长江药业(01558):选举唐新发为董事长
强大研发管线堆叠,东阳光药商业化实力正持续验证
市场资讯 · 05-28
强大研发管线堆叠,东阳光药商业化实力正持续验证
东阳光长江药业(01558)下跌5.08%,报11.22元/股
金融界 · 05-17
东阳光长江药业(01558)下跌5.08%,报11.22元/股
东阳光长江药业(01558)股价下跌5.076%,现价港币$11.22
阿斯达克财经 · 05-17
东阳光长江药业(01558)股价下跌5.076%,现价港币$11.22
智通港股早知道 | 多部委酝酿推出房地产“重大举措” 港证监容许简化规定延伸至主动型ETF
智通财经 · 05-17
智通港股早知道 | 多部委酝酿推出房地产“重大举措” 港证监容许简化规定延伸至主动型ETF
东阳光长江药业(01558)拟派发特别股息每股1.5港元
智通财经 · 05-16
东阳光长江药业(01558)拟派发特别股息每股1.5港元
[路演]九州通:公司与东阳光药、拜耳康王、阿斯利康等国内外知名企业开展了深度战略合作
全景网 · 05-16
[路演]九州通:公司与东阳光药、拜耳康王、阿斯利康等国内外知名企业开展了深度战略合作
聚焦市场大潜力领域,东阳光药开启价值创造正循环
和讯 · 05-16
聚焦市场大潜力领域,东阳光药开启价值创造正循环
创新驱动驶入发展快车道,东阳光药拟以介绍方式登陆资本市场
和讯 · 05-15
创新驱动驶入发展快车道,东阳光药拟以介绍方式登陆资本市场
东阳光药:多元化管线布局驱动成长,商业化能力助力稳健增长
每日经济新闻 · 05-13
东阳光药:多元化管线布局驱动成长,商业化能力助力稳健增长
东阳光长江药业公布将于5月13日上午起复牌
新浪港股 · 05-13
东阳光长江药业公布将于5月13日上午起复牌
加载更多
公司概况
公司名称:
东阳光长江药业
所属市场:
SEHK
上市日期:
--
主营业务:
宜昌东阳光长江药业股份有限公司是一家主要从事药品生产及销售业务的中国公司。其业务还包括药品的研发、营销及分销。该公司产品包括抗病毒药物、内分泌及代谢药物及心血管药物。其核心产品组合包括“可威”、“尔同舒”、“欧美宁”、“欣海宁”及 “喜宁”。
发行价格:
--
{"stockData":{"symbol":"01558","market":"HK","secType":"STK","nameCN":"东阳光长江药业","latestPrice":9.14,"timestamp":1719973106242,"preClose":8.99,"halted":0,"volume":29400,"delay":0,"floatShares":653767700,"shares":879967700,"eps":2.4212856,"marketStatus":"交易中","marketStatusCode":2,"change":0.15,"latestTime":"07-03 10:19:09","open":8.99,"high":9.14,"low":8.99,"amount":266392,"amplitude":0.016685,"askPrice":9.14,"askSize":2000,"bidPrice":9.11,"bidSize":2400,"shortable":3,"etf":0,"ttmEps":2.416550786469443,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1719979200000},"adr":0,"listingDate":1451318400000,"adjPreClose":8.99,"openAndCloseTimeList":[[1719970200000,1719979200000],[1719982800000,1719993600000]],"volumeRatio":0.215821,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01558","defaultTab":"news","newsList":[{"id":"2446545740","title":"东阳光长江药业早盘涨超3% 公司有望获纳入港股通名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2446545740","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446545740?lang=zh_cn&edition=full","pubTime":"2024-06-28 11:36","pubTimestamp":1719545783,"startTime":"0","endTime":"0","summary":"东阳光长江药业(01558)早盘上涨3.47%,现报9.25港元,成交额114.81万港元。\n 据悉,恒生综合指数每年都会在6月30日和12月31日进行定期检讨。据最新数据显示,截至2024年6月19日,港股上市公司要想进入港股通,其检讨期内港股平均月末流通市值门槛大约为57.39亿港元。目前公司港股流通市值已超60亿港元,显著高于目前的“入通门槛”,有极大的机会利用“630”时间节点纳入港股通名单。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-28/doc-incaheim4620290.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-28/doc-incaheim4620290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["07226","HSCEI","HSTECH","BK1191","BK1515","01558"],"gpt_icon":0},{"id":"2446545810","title":"港股异动 | 东阳光长江药业(01558)早盘涨超3% 恒生综合指数即将进行定期检讨 公司有望获纳入港股通名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2446545810","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446545810?lang=zh_cn&edition=full","pubTime":"2024-06-28 11:27","pubTimestamp":1719545274,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,东阳光长江药业早盘涨超3%,截至发稿,涨3.36%,报9.24港元,成交额114.81万港元。据悉,恒生综合指数每年都会在6月30日和12月31日进行定期检讨。据最新数据显示,截至2024年6月19日,港股上市公司要想进入港股通,其检讨期内港股平均月末流通市值门槛大约为57.39亿港元。目前公司港股流通市值已超60亿港元,显著高于目前的“入通门槛”,有极大的机会利用“630”时间节点纳入港股通名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","YANG","BK1191","BK1515","07226","HSCI","HSCEI","01558"],"gpt_icon":0},{"id":"2446582431","title":"路演实录|东阳光长江药业(01558):聚焦三大领域 一体化释放长期价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2446582431","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446582431?lang=zh_cn&edition=full","pubTime":"2024-06-27 18:23","pubTimestamp":1719483800,"startTime":"0","endTime":"0","summary":"截止当前,拥有两大国家重点实验室,涵盖29项国家重大专项,以及140余个在研项目。目前海外获批品种达70个。目前,公司围绕巨大市场和医疗需求,聚焦感染、慢病、肿瘤三大领域,做同类首创或者同类最佳的药物。其中,一款GLP-1与FGF21双靶新药在海外一期、国内二期临床中。此外,AI平台也是东阳光药发力点。流感领域将布局新药物,儿童抗感染领域将关注肺炎支原体、抗生素、合胞病毒和鼻炎等细分市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01558","BK1191"],"gpt_icon":0},{"id":"2446107853","title":"东阳光长江药业(01558)上涨5.09%,报9.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446107853","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446107853?lang=zh_cn&edition=full","pubTime":"2024-06-25 09:57","pubTimestamp":1719280635,"startTime":"0","endTime":"0","summary":"6月25日,东阳光长江药业(01558)盘中上涨5.09%,截至09:57,报9.5元/股,成交243.38万元。宜昌东阳光长江药业股份有限公司是一家专注于抗病毒、内分泌及代谢性疾病、心血管疾病等治疗领域产品的研发、生产及销售的制药企业,拥有覆盖全国的产品分销网络,其核心产品磷酸奥司他韦是中国抗流感病毒市场的主导产品。截至2015年年末,公司在国内生产、推广及销售了33款医药产品,2013至2015年,其磷酸奥司他韦产品在中国区销量名列第一。截至2023年年报,东阳光长江药业营业总收入62.95亿元、净利润19.93亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/25095741176242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","01558","BK1191"],"gpt_icon":0},{"id":"2446853218","title":"东阳光长江药业盘中异动 股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446853218","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446853218?lang=zh_cn&edition=full","pubTime":"2024-06-25 09:57","pubTimestamp":1719280629,"startTime":"0","endTime":"0","summary":"2024年06月25日早盘09时57分,东阳光长江药业股票出现异动,股价快速拉升5.10%。东阳光长江药业股票所在的药品行业中,整体涨幅为0.05%。其相关个股中,君圣泰医药-B、东阳光长江药业、复星医药涨幅较大,振幅较大的相关个股有君圣泰医药-B、三爱健康集团、东阳光长江药业,振幅分别为11.84%、5.00%、3.98%。东阳光长江药业公司简介:宜昌东阳光长江药业股份有限公司是一家主要从事药品生产及销售业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240625095709941f0c22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240625095709941f0c22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","01558"],"gpt_icon":0},{"id":"2444290428","title":"一体化合并加速释放研产销竞争优势,“入通”或为东阳光长江药业(01558)估值跃迁起点","url":"https://stock-news.laohu8.com/highlight/detail?id=2444290428","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444290428?lang=zh_cn&edition=full","pubTime":"2024-06-20 19:24","pubTimestamp":1718882649,"startTime":"0","endTime":"0","summary":"手握“流感药王”进入港股通的几率陡增,东阳光长江药业股价反弹在即?也就是说,目前的东阳光长江药业无论在流通市值还是流动性方面均已触及入通门槛,今年月底的定期检讨将有极大概率被纳入港股通名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406201933039f52800c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406201933039f52800c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2444103409","title":"东阳光长江药业06月18日主力资金流入21万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2444103409","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444103409?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:16","pubTimestamp":1718698567,"startTime":"0","endTime":"0","summary":"06月18日, 东阳光长江药业股价跌0.11%,报收9.05元,成交金额1265万元,换手率0.22%,振幅2.98%,量比0.93。东阳光长江药业今日主力资金净流入21万元,连续3日净流入,上一交易日主力净流入66万元,今日环比减少68.18%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为46.15%,平均涨幅为2.73%。该股近5个交易日下跌0.33%,主力资金累计净流入85万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入61万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181616319f499ea9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181616319f499ea9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","01558","BK1191"],"gpt_icon":0},{"id":"2442599313","title":"东阳光长江药业06月11日获主力加仓234万元 环比增加333.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442599313","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442599313?lang=zh_cn&edition=full","pubTime":"2024-06-11 16:16","pubTimestamp":1718093813,"startTime":"0","endTime":"0","summary":"06月11日, 东阳光长江药业股价跌3.19%,报收9.10元,成交金额2455万元,换手率0.41%,振幅3.51%,量比1.69。东阳光长江药业今日主力资金净流入234万元,上一交易日主力净流入54万元,今日环比增加333.33%。该股近5个交易日下跌3.60%,主力资金累计净流入440万元;近20日主力资金累计净流出3783万元,其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406111617229f3037bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406111617229f3037bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","01558"],"gpt_icon":0},{"id":"2441992500","title":"东阳光长江药业:发布2023年年报补充公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2441992500","media":"金融界港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441992500?lang=zh_cn&edition=full","pubTime":"2024-06-07 22:46","pubTimestamp":1717771617,"startTime":"0","endTime":"0","summary":"金融界6月7日消息,东阳光长江药业发布了关于2023年年报的补充公告。公告明确,公司董事会对本集团的风险管理和内部监控系统负责,全力确保主要影响公司业绩的风险得到充分识别和管理,合理防止出现严重失实陈述或损失。除此之外,公告也阐述了董事会对公司内部监控措施的有效性及对未来风险管理的信心。此外,补充公告并不影响年报其他内容的正确性,年报的其他所有信息保持不变。\n\n\r\n 责任编辑:钟离","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/07224640956630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","01558","BK1515"],"gpt_icon":0},{"id":"2441056056","title":"东阳光长江药业(01558):选举唐新发为董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2441056056","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441056056?lang=zh_cn&edition=full","pubTime":"2024-06-07 18:48","pubTimestamp":1717757315,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光长江药业 发布公告,经股东周年大会的批准,蒋均才、王丹津、陈浩及李爽被重新选举为第四届董事会执行董事,唐新发被重新选举为第四届董事会非执行董事以及唐建新、向凌及李学臣被重新选举为第四届董事会独立非执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1132915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01558","BK1515"],"gpt_icon":0},{"id":"2438360692","title":"强大研发管线堆叠,东阳光药商业化实力正持续验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2438360692","media":"市场资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438360692?lang=zh_cn&edition=full","pubTime":"2024-05-28 09:21","pubTimestamp":1716859319,"startTime":"0","endTime":"0","summary":"东阳光药坚持为全球患者提供创新、可负担及优质的药物,力争成为一家全球领先的综合性制药公司。据了解,东阳光药拥有丰富而极具竞争力的药物管线,确保公司在医药研发领域处于领先地位,并处于可持续发展的良性状态,这也显示出公司在未来发展中强劲的增长潜力。据统计,东阳光药在境内推广及销售合共40多款医药产品,最大限度覆盖全国市场。此外,东阳光药的新药已有1款1类创新药品纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528092203956bc480&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528092203956bc480&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01558","BK1515"],"gpt_icon":0},{"id":"2436962597","title":"东阳光长江药业(01558)下跌5.08%,报11.22元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2436962597","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436962597?lang=zh_cn&edition=full","pubTime":"2024-05-17 15:36","pubTimestamp":1715931389,"startTime":"0","endTime":"0","summary":"5月17日,东阳光长江药业(01558)盘中下跌5.08%,截至15:36,报11.22元/股,成交3465.78万元。宜昌东阳光长江药业股份有限公司是一家专注于抗病毒、内分泌及代谢性疾病、心血管疾病等治疗领域产品的研发、生产及销售的制药企业,拥有覆盖全国的产品分销网络,其核心产品磷酸奥司他韦是中国抗流感病毒市场的主导产品。截至2015年年末,公司在国内生产、推广及销售了33款医药产品,2013至2015年,其磷酸奥司他韦产品在中国区销量名列第一。截至2023年年报,东阳光长江药业营业总收入62.95亿元、净利润19.93亿元。5月16日,每股派港币1.5元(董事会预案)。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/17153640684893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK1515","01558"],"gpt_icon":0},{"id":"2436496248","title":"东阳光长江药业(01558)股价下跌5.076%,现价港币$11.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2436496248","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436496248?lang=zh_cn&edition=full","pubTime":"2024-05-17 15:35","pubTimestamp":1715931300,"startTime":"0","endTime":"0","summary":"[下跌股]东阳光长江药业(01558) 股价在下午03:35比前收市价下跌5.076%,现股价为港币$11.22。至目前为止,今日最高价为$11.84,而最低价为$11.22。总成交量为301.08万股,总成交金额为港币$3.451千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2405171554/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","01558","BK1515"],"gpt_icon":0},{"id":"2436936119","title":"智通港股早知道 | 多部委酝酿推出房地产“重大举措” 港证监容许简化规定延伸至主动型ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=2436936119","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436936119?lang=zh_cn&edition=full","pubTime":"2024-05-17 07:39","pubTimestamp":1715902766,"startTime":"0","endTime":"0","summary":"多部委成立联合工作组 酝酿推出房地产“重大举措”房地产行业持续颓势,意在消化存量房产和优化增量住房的政策措施正在酝酿中。在下午的政策吹风会之前,5月17日上午国务院将组织召开房地产工作相关会议,届时或将宣布房地产领域相关举措。制定出台专项政策,加大资金支持力度。“目前有口头告知,但尚未接到正式通知。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FDN","LU0588546209.SGD","BK1095","BK1502","BK4588","BK4585","89888","HSCEI","LU0039217434.USD","LU0821914370.USD","LU1044876610.USD","LU0868486357.SGD","09888","02618","LU0708995583.HKD","LU0327786744.USD","LU0228367735.SGD","BIDU","BK1609","BK1191","BK1575","LU0140636845.USD","LU0456827905.SGD","09979","BK1610","LU1048588211.SGD","00631","LU0588545904.SGD","BK1249","IE0034224299.USD","LU0456846285.SGD","HSTECH","LU0029875118.USD","LU1328615791.USD","LU0072462343.USD","89618","LU0456842615.SGD","LU0229945570.USD","SG9999002828.SGD","LU0762540952.USD","LU1366334651.USD","LU0359202008.SGD","LU0320764599.SGD","09618","LU0588545730.USD","07226","01558","YANG","LU0831093199.SGD","LU0819121731.USD"],"gpt_icon":0},{"id":"2435622202","title":"东阳光长江药业(01558)拟派发特别股息每股1.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435622202","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435622202?lang=zh_cn&edition=full","pubTime":"2024-05-16 17:48","pubTimestamp":1715852882,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光长江药业(01558)发布公告,该公司拟派发特别股息每股1.5港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01558","BK1515"],"gpt_icon":0},{"id":"2435626983","title":"[路演]九州通:公司与东阳光药、拜耳康王、阿斯利康等国内外知名企业开展了深度战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2435626983","media":"全景网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435626983?lang=zh_cn&edition=full","pubTime":"2024-05-16 16:27","pubTimestamp":1715848020,"startTime":"0","endTime":"0","summary":"九州通总经理贺威回复称,公司与东阳光药、拜耳康王、阿斯利康、诺华制药、华海药业、广西金嗓子、利君制药、卫材(中国)药业等国内外知名企业开展深度战略合作及业务落地执行,围绕产品全周期营销服务需求,建立产品全价值链运营体系,为其提供全渠道品牌营销解决方案,增强产品市场竞争力,提高产品市场占有率。据介绍,九州通品牌运营能力持续增强,合作的重点品种表现亮眼,收获客户认可及行业奖项,实现口碑、业务双丰收。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405161627298b0e2ebc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405161627298b0e2ebc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600998","BK1515","01558","AZN","BK1191"],"gpt_icon":0},{"id":"2435611969","title":"聚焦市场大潜力领域,东阳光药开启价值创造正循环","url":"https://stock-news.laohu8.com/highlight/detail?id=2435611969","media":"和讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435611969?lang=zh_cn&edition=full","pubTime":"2024-05-16 10:17","pubTimestamp":1715825823,"startTime":"0","endTime":"0","summary":"东阳光药聚焦感染、慢病、肿瘤三大极具市场潜力和重大未满足临床需求的重点领域,以“创新”作为核心驱动力,致力于在全球市场开发出具有同类首创或同类最佳潜力的创新产品。今年3月,东阳光长江药业发布公告表示,母公司东阳光药正考虑以换股方式吸收合并东阳光长江药业。5月10日,东阳光长江药业发布公告进一步表示,东阳光药已与东阳光长江药业订立合并协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405161023308b0d12f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405161023308b0d12f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2435639508","title":"创新驱动驶入发展快车道,东阳光药拟以介绍方式登陆资本市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2435639508","media":"和讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435639508?lang=zh_cn&edition=full","pubTime":"2024-05-15 11:33","pubTimestamp":1715744010,"startTime":"0","endTime":"0","summary":"在相关条件完成后,东阳光长江药业将从联交所除牌,东阳光药H股会以介绍方式在联交所主板上市。目前东阳光药重点聚焦感染、慢病、肿瘤三大重点领域。在过往的20年,东阳光药以丰富的研发经验铸就了卓越佳绩,若东阳光药顺利完成换股合并,并以介绍方式成功上市,依托于丰富多元的创新管线、研产销一体化能力,公司有望进一步贴合不断升温的市场预期,加速形成正向价值循环。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405151133328b09c9ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405151133328b09c9ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2435390264","title":"东阳光药:多元化管线布局驱动成长,商业化能力助力稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2435390264","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435390264?lang=zh_cn&edition=full","pubTime":"2024-05-13 12:16","pubTimestamp":1715573766,"startTime":"0","endTime":"0","summary":"此次入围榜单,充分体现了东阳光药在中国医药行业的领军地位。研发创新驱动成长,多元化管线布局东阳光药拥有出色的研发能力。近日,胰岛素国家续采落地,东阳光药成为本次接续采购最大的受益者之一。总体来看,凭借其强大的研发实力、多元化的产品管线、突出的商业化能力和国际化的战略布局,东阳光药不仅在国内市场取得了显","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131219328760969e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131219328760969e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1161","06978","BK1515","BK1191","BK1574","01558"],"gpt_icon":0},{"id":"2435360245","title":"东阳光长江药业公布将于5月13日上午起复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2435360245","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435360245?lang=zh_cn&edition=full","pubTime":"2024-05-13 09:30","pubTimestamp":1715563817,"startTime":"0","endTime":"0","summary":"东阳光长江药业(01558)发布公告,该公司股份将于2024年5月13日上午9时正起恢复买卖。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-13/doc-inauzwwm2185092.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-13/doc-inauzwwm2185092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1191","01558","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hec-changjiang.com","stockEarnings":[{"period":"1week","weight":-0.0186},{"period":"1month","weight":-0.0919},{"period":"3month","weight":-0.1901},{"period":"6month","weight":-0.1064},{"period":"1year","weight":0.3358},{"period":"ytd","weight":-0.0527}],"compareEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0624},{"period":"6month","weight":0.0675},{"period":"1year","weight":-0.0796},{"period":"ytd","weight":0.0423}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜昌东阳光长江药业股份有限公司是一家主要从事药品生产及销售业务的中国公司。其业务还包括药品的研发、营销及分销。该公司产品包括抗病毒药物、内分泌及代谢药物及心血管药物。其核心产品组合包括“可威”、“尔同舒”、“欧美宁”、“欣海宁”及 “喜宁”。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052152},{"month":2,"riseRate":0.777778,"avgChangeRate":0.088442},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.0661},{"month":4,"riseRate":0.666667,"avgChangeRate":0.018306},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.018369},{"month":6,"riseRate":0.666667,"avgChangeRate":0.070024},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.05925},{"month":8,"riseRate":0.125,"avgChangeRate":-0.056274},{"month":9,"riseRate":0.5,"avgChangeRate":-0.046672},{"month":10,"riseRate":0.5,"avgChangeRate":0.037128},{"month":11,"riseRate":0.75,"avgChangeRate":0.145001},{"month":12,"riseRate":0.5,"avgChangeRate":0.005825}],"exchange":"SEHK","name":"东阳光长江药业","nameEN":"HEC CJ PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光长江药业(01558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光长江药业(01558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光长江药业,01558,东阳光长江药业股票,东阳光长江药业股票老虎,东阳光长江药业股票老虎国际,东阳光长江药业行情,东阳光长江药业股票行情,东阳光长江药业股价,东阳光长江药业股市,东阳光长江药业股票价格,东阳光长江药业股票交易,东阳光长江药业股票购买,东阳光长江药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光长江药业(01558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光长江药业(01558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}